Expert Interview
Discussing the ISM treatment landscape and the potential of AYVAKIT (avapritinib) with current prescribers
Ticker(s): BPMCInstitution: RUSH University
- Medical Oncologist and Hematologist, Professor of Medicine and Director, Section of BMT/Cell Therapy in the Division of Hematology, Oncology, and Cell Therapy at Rush University.
- Currently manages 40 patients with Indolent Systemic Mastocytosis and prescribes AYVAKIT.
- Clinical interest in hematologic malignancies and hematopoietic cell transplant ad his research interest is in the conduct of clinical trials and the characterization of infectious complications of hematologic malignancy care.
What are the potential benefits and risks associated with AYVAKIT?
What could be the market size and potential opportunity for AYVAKIT?
How does AYVAKIT compare to competitor drugs or treatment options in terms of efficacy and safety?
Added By: chanell_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
